UK GLP-1 prices & evidence, made clearer.Our comparison standards
Follow the evidence

The source library.

Authoritative references used across the medication library. Each guide links the sources supporting its specific sections.

Medicine and safety references

  1. Mounjaro KwikPen: UK Summary of Product Characteristics
    Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
  2. Mounjaro KwikPen: patient information leaflet
    Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
  3. MHRA authorises Mounjaro for weight management and weight loss
    MHRA · Accessed 19 November 2026
  4. Wegovy FlexTouch: UK Summary of Product Characteristics
    Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  5. Wegovy FlexTouch: patient information leaflet
    Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  6. MHRA approves up to 7.2 mg semaglutide for adults with obesity
    MHRA · Accessed 19 November 2026
  7. Wegovy tablets: UK Summary of Product Characteristics
    Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  8. Wegovy tablets: patient information leaflet
    Novo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  9. First GLP-1 tablet for weight loss approved in the UK
    MHRA · Accessed 19 November 2026
  10. Foundayo: UK Summary of Product Characteristics, revised 3 November 2026
    Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
  11. Foundayo: patient information leaflet
    Eli Lilly / electronic medicines compendium · Accessed 19 November 2026
  12. UK authorises orforglipron for weight management and type 2 diabetes
    MHRA · Accessed 19 November 2026
  13. SURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity
    New England Journal of Medicine · Accessed 19 November 2026
  14. SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
    New England Journal of Medicine · Accessed 19 November 2026
  15. STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
    New England Journal of Medicine · Accessed 19 November 2026
  16. STEP 2: Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes
    The Lancet / PubMed · Accessed 19 November 2026
  17. STEP 4: Continued semaglutide versus placebo for weight loss maintenance
    JAMA / PubMed · Accessed 19 November 2026
  18. STEP UP: Once-weekly semaglutide 7.2 mg in adults with obesity
    The Lancet Diabetes & Endocrinology / PubMed · Accessed 19 November 2026
  19. OASIS 4: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
    New England Journal of Medicine · Accessed 19 November 2026
  20. Wegovy oral formulation: European regulatory assessment report
    European Medicines Agency · Accessed 19 November 2026
  21. ATTAIN-1: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
    New England Journal of Medicine · Accessed 19 November 2026
  22. ATTAIN-2: Orforglipron for obesity in people with type 2 diabetes
    The Lancet / PubMed · Accessed 19 November 2026
  23. TA1026: Tirzepatide for managing overweight and obesity
    NICE · Accessed 19 November 2026
  24. TA875: Semaglutide for managing overweight and obesity
    NICE · Accessed 19 November 2026
  25. Prescribing, reviewing and stopping tirzepatide
    NICE · Accessed 19 November 2026
  26. Overweight and obesity management: medicines and surgery
    NICE · Accessed 19 November 2026
  27. Weight management injections: NHS England patient information
    NHS England · Accessed 19 November 2026
  28. Interim commissioning guidance for tirzepatide
    NHS England · Accessed 19 November 2026
  29. Semaglutide: uses, side effects and precautions
    NHS · Accessed 19 November 2026
  30. Overweight and obesity in adults
    NHS · Accessed 19 November 2026
  31. GLP-1 medicines for weight loss and diabetes: what you need to know
    MHRA · Accessed 19 November 2026
  32. GLP-1 medicines: strengthened warnings on acute pancreatitis
    MHRA · Accessed 19 November 2026
  33. MHRA updates semaglutide guidance on very rare NAION
    MHRA · Accessed 19 November 2026
  34. GLP-1 medicines: potential aspiration risk during anaesthesia or deep sedation
    MHRA · Accessed 19 November 2026
  35. Dehydration: symptoms and when to get help
    NHS · Accessed 19 November 2026
  36. Anaphylaxis: emergency symptoms and action
    NHS · Accessed 19 November 2026
  37. Gallstones: symptoms and urgent help
    NHS · Accessed 19 November 2026
  38. Low blood sugar: hypoglycaemia
    NHS · Accessed 19 November 2026
  39. How to keep safe when getting medicines or treatment online
    General Pharmaceutical Council and UK health organisations · Accessed 19 November 2026
  40. MHRA warns against buying weight loss medicines without a prescription
    MHRA · Accessed 19 November 2026
  41. GLP-1 receptor agonists in pregnancy
    UK Teratology Information Service / BUMPS · Accessed 19 November 2026
  42. Semaglutide tablets: NHS Scotland non-submission advice, September 2026
    Scottish Medicines Consortium · Accessed 19 November 2026
  43. SURMOUNT-4: Continued tirzepatide for maintenance of weight reduction
    JAMA · Accessed 19 November 2026
  44. Weight regain after semaglutide withdrawal: STEP 1 extension
    Diabetes, Obesity and Metabolism · Accessed 19 November 2026
  45. GLP-1 treatment: nutritional considerations for prescribing clinicians
    NHS Bath and North East Somerset, Swindon and Wiltshire ICB · Accessed 19 November 2026
  46. Patient information: GLP-1 medicines and preparing for surgery
    Centre for Perioperative Care / UK multidisciplinary consensus group · Accessed 19 November 2026
  47. The Eatwell Guide
    NHS · Accessed 19 November 2026
  48. Travelling with medicines and medical equipment
    UK Civil Aviation Authority · Accessed 19 November 2026
  49. Constipation in adults
    NHS · Accessed 19 November 2026
  50. Medicines and travel
    National Travel Health Network and Centre · Accessed 19 November 2026

Price provenance

Pharmacy amounts are imported from Mango Market’s price index under permission confirmed by the site owner. These secondary-source observations are different from independently verified checkout quotes. Read the methodology.

For readers and automated tools

The canonical HTML pages contain the readable source context. The structured price snapshot preserves observation dates and unknown fees; it should not be interpreted as a live offer API. An index for automated readers points to key pages. Machine readability does not certify accuracy or guarantee inclusion in AI answers.